Nuvig Therapeutics Appoints David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board Chair

Menlo Park, Calif., September 9, 2025 – Nuvig Therapeutics, Inc. (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced the appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and member of the Board of Directors and James Mackay, Ph.D., as Independent Board Chair.